Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 16(3): e0248214, 2021.
Article in English | MEDLINE | ID: mdl-33730110

ABSTRACT

The characterization of pulmonary arterial hypertension (PAH) relies mainly on right heart catheterization (RHC). Electrical impedance tomography (EIT) provides a non-invasive estimation of lung perfusion that could complement the hemodynamic information from RHC. To assess the association between impedance variation of lung perfusion (ΔZQ) and hemodynamic profile, severity, and prognosis, suspected of PAH or worsening PAH patients were submitted simultaneously to RHC and EIT. Measurements of ΔZQ were obtained. Based on the results of the RHC, 35 patients composed the PAH group, and eight patients, the normopressoric (NP) group. PAH patients showed a significantly reduced ΔZQ compared to the NP group. There was a significant correlation between ΔZQ and hemodynamic parameters, particularly with stroke volume (SV) (r = 0.76; P < 0.001). At 60 months, 15 patients died (43%) and 1 received lung transplantation; at baseline they had worse hemodynamics, and reduced ΔZQ when compared to survivors. Patients with low ΔZQ (≤154.6%.Kg) presented significantly worse survival (P = 0.033). ΔZQ is associated with hemodynamic status of PAH patients, with disease severity and survival, demonstrating EIT as a promising tool for monitoring patients with pulmonary vascular disease.


Subject(s)
Blood Pressure/physiology , Body Composition/physiology , Hemodynamics/physiology , Pulmonary Arterial Hypertension/physiopathology , Adult , Electric Impedance , Female , Humans , Male , Middle Aged , Tomography , Young Adult
2.
Eur Respir Rev ; 28(151)2019 Mar 31.
Article in English | MEDLINE | ID: mdl-30918022

ABSTRACT

Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.


Subject(s)
Anticoagulants/therapeutic use , Blood Coagulation/drug effects , Fibrinolytic Agents/therapeutic use , Neoplasms/complications , Thrombosis/drug therapy , Anticoagulants/adverse effects , Fibrinolytic Agents/adverse effects , Hemorrhage/chemically induced , Humans , Incidence , Neoplasms/blood , Neoplasms/mortality , Prevalence , Recurrence , Risk Assessment , Risk Factors , Thrombosis/blood , Thrombosis/etiology , Thrombosis/mortality , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...